Seattle Genetics, Inc. Reports First Quarter 2013 Financial Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2013. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline and technology and upcoming milestones.
Help employers find you! Check out all the jobs and post your resume.
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported financial results for the first quarter ended March 31, 2013. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, progress with its antibody-drug conjugate (ADC) pipeline and technology and upcoming milestones.
Help employers find you! Check out all the jobs and post your resume.